Hospital General Universitario De Albacete — Clinical Trial Site

55 Registered trials

27 Currently recruiting

Organisation

Hospital General Universitario De Albacete

Location

Albacete, Spain

Identifier

ORG-100045775

Address

Calle Hermanos Falco 37, 02006, Spain

Departments

#2319:servicio de neurología
7213: Neurology
Allergology
Anestesia
Cardiolgy
CARDIOLOGY
Clinical Haematology
ES049A: Hematología
Geriatria
Geriatrics
Hematología
Hematology
Intensive medicine
Medical Oncology
Medicina Interna
Neurología
Neurology
Neurology Department
Neurology Service
OFTALMOLOGIA
ONCOLOGIA
Oncology
Oncology Service
Pneumology
Servicio de Alergia
Servicio de hematología
Servicio de Neurología
Servicio de Oncología y Hematología Pediátricas

Clinical trials at this site (55)

Search interface

CLINICAL TRIAL WITH APROTININ IN THE ACUTE RESPIRATORY DISTRESS SYNDROME TREATMENT Pending

2025-520826-39-00 ACUTE RESPIRATORY DISTRESS SYNDROME 5
A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf… Pending

2025-521230-29-00 Allergic rhinoconjunctivitis to Dermatophagoides pteron 5
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Pending

2025-521709-42-00 Allergic rhinoconjunctivitis with or without asthma due 5
Grass Immunotherapy for Rhinitis and Asthma (GIRA) Pending

2025-521736-10-00 Allergic rhinoconjunctivitis with or without controlled 5
Dose determination study of Phleum pratense allergenic extract for immunotherapy treatment, administered via sublingual route, standardized … Pending

2025-522730-31-00 Allergic rhinitis/rhinoconjunctivitis caused by grass p 4
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia… Pending

2025-523238-17-00 Acute myeloid leukemia 4
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Pa… Pending

2025-524308-31-00 Acute myeloid leukemia 4
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting

2024-512436-29-00 CARDIOVASCULAR DISEASES 11 2026-03-27
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting

2024-513911-28-00 Acute Ischemic Stroke 10 2026-03-04
Assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke. Recruiting

2024-519551-29-00 Acute cerebral ischemic stroke 5 2025-08-21
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Acute myeloid leukemia 5 2025-05-05
IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting

2024-514517-35-00 Acute myeloid leukemia 5 2025-02-27
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting

2025-522979-29-00 Acute myeloid leukemia 5 2026-04-30
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard… Recruiting

2025-521634-29-00 Acute Myeloid Leukemia 5 2026-03-02
EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting

2025-522701-38-00 SUBRETINAL HYPERREFLECTIVE MATERIAL 6 2026-02-26
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re… Recruiting

2024-515201-26-00 Small cell lung cancer (SCLC) 4 2025-12-09
Inhaled sedation in the critically ill patient Recruiting

2024-518521-14-00 Critical condition 6 2025-10-17
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION) Recruiting

2024-519521-37-01 Acute ischemic stroke 10 2025-07-30